Submitted on July 13, 2017 - USP's comment letter to FDA on the approval application for the proposed biosimilar to Avastin (bevacizumab).
FDA-Ad-Com-Biosimilars-Statement.pdf
(76.73 KB)
Submitted on July 13, 2017 - USP's comment letter to FDA on the approval application for the proposed biosimilar to Avastin (bevacizumab).